Merck Group appoints head of global procurement
Friedheim Felten takes up role on 1 April
Taking up the role on 1 April, Felten succeeds Friedrich Schmitt, who has headed the function since 1997 and will be retiring at the end of July. Felten will report to Michael Becker, chief financial officer.
Corporate procurement is responsible for purchasing production materials such as pharmaceutical raw materials and chemicals, and for procuring technical components such as production and laboratory equipment as well as services such as pharmaceutical research and development. The 500 members of the global matrix organisation handle an annual purchasing volume of around b4.5bn.
Felten joined Merck in July 2009 as head of procurement for Services. He has many years of management experience in purchasing and in other functions at international companies, including DHL Global Forwarding in Singapore, DHL Logistics in London, and BASF AG in Ludwigshafen, as well as various BASF subsidiaries in Asia.
You may also like
Finance
![Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal]()
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal
The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Finance
![Prescient completes integration of Uptake and Dolon under single global brand]()
Prescient completes integration of Uptake and Dolon under single global brand
Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
Finance
![AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes]()
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes
The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
